Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups.

Mult Scler. 2017 Mar 1:1352458517695468. doi: 10.1177/1352458517695468. [Epub ahead of print]

PMID:
28304217
2.

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.

Mäurer M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, Miller AE, Dive-Pouletty C, Bozzi S, O'Connor PW.

Mult Scler Relat Disord. 2016 May;7:33-40. doi: 10.1016/j.msard.2016.02.012. Epub 2016 Feb 17.

3.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

4.

Reducing clinical trial risk in multiple sclerosis.

De Gasperis-Brigante CD, Parker JL, O'Connor PW, Bruno TR.

Mult Scler Relat Disord. 2016 Jan;5:81-8. doi: 10.1016/j.msard.2015.11.007. Epub 2015 Nov 11.

PMID:
26856949
5.

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW.

Mult Scler J Exp Transl Clin. 2015 Dec 7;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015 Jan-Dec.

6.

Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.

O'Connor PW, Kremenchutzky M.

Can J Neurol Sci. 2015 Nov;42(6):372-80. doi: 10.1017/cjn.2015.296. Epub 2015 Oct 27. Review. No abstract available.

PMID:
26503087
7.

Established disease-modifying treatments in relapsing-remitting multiple sclerosis.

Oh J, O'Connor PW.

Curr Opin Neurol. 2015 Jun;28(3):220-9. doi: 10.1097/WCO.0000000000000202. Review.

PMID:
25923124
8.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A, Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Can J Neurol Sci. 2015 May;42(3):159-67. doi: 10.1017/cjn.2015.24. Epub 2015 Apr 21.

9.

Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.

Oh J, O'Connor PW.

Curr Opin Neurol. 2015 Jun;28(3):230-6. doi: 10.1097/WCO.0000000000000203. Review.

PMID:
25887773
10.

Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment.

Oh J, O'Connor PW.

Nat Rev Neurol. 2015 Feb;11(2):76-8. doi: 10.1038/nrneurol.2014.259. Epub 2015 Jan 13. Review.

PMID:
25582444
11.

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.

Oh J, O'Connor PW.

Ther Adv Neurol Disord. 2014 Sep;7(5):239-52. doi: 10.1177/1756285614546855. Review.

12.

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group.

Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.

PMID:
25192851
13.

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW.

J Neurol. 2014 Sep;261(9):1781-8. doi: 10.1007/s00415-014-7395-7. Epub 2014 Jun 28.

14.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

15.

Disease-modifying agents in multiple sclerosis.

O'Connor PW, Oh J.

Handb Clin Neurol. 2014;122:465-501. doi: 10.1016/B978-0-444-52001-2.00021-2. Review.

PMID:
24507532
16.

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V.

Eur Neurol. 2014;71(3-4):173-9. doi: 10.1159/000355530. Epub 2014 Jan 21.

PMID:
24457374
17.

Teriflunomide.

Oh J, O'Connor PW.

Neurol Clin Pract. 2013 Jun;3(3):254-260.

18.

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L.

J Neurol. 2013 Oct;260(10):2472-80. doi: 10.1007/s00415-013-6979-y. Epub 2013 Jul 14.

19.

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW.

Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.

20.

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Oh J, O'Connor PW.

CNS Drugs. 2013 Aug;27(8):591-609. doi: 10.1007/s40263-013-0080-z. Review.

PMID:
23801528

Supplemental Content

Loading ...
Support Center